OCD LIFU Target Engagement
Pilot Study to Investigate Brain Targets for Neuromodulation in Obsessive-compulsive Disorder
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Marshall Nambiar, MS
- 电话号码:215-746-8901
- 邮箱:marshall.nambiar@pennmedicine.upenn.edu
学习地点
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- 招聘中
- University of Pennsylvania
-
首席研究员:
- Katherine Scangos, MD, PhD
-
接触:
- Marshall Nambiar, MS
- 电话号码:215-746-8901
- 邮箱:marshall.nambiar@pennmedicine.upenn.edu
-
-
参与标准
资格标准
适合学习的年龄
- 成人
接受健康志愿者
描述
Inclusion Criteria:
1. Participants must be enrolled in the IRB #853085 study
The inclusion criteria for the IRB #853085 study, which are also included in this trial are:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Adults aged 18-60 years old
- Chronic OCD (5 years preceding date of enrollment), diagnosed as per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition guidelines (DSM-5)
- Presence of obsessions, compulsions, or both time-consuming obsessions and compulsions that take more than one hour a day or cause significant distress or impairment in social, occupation, or other important areas of functioning Obsessive-compulsive symptoms that are not attributable to the physiological effects of a substance (e.g., a drug of abuse, a medication) or another medical condition
- Disturbance not better explained by the symptoms of another mental disorder listed in the DSM-5 Severe OCD symptoms, as defined by Y-BOCS I score of 28 or higher, within two weeks prior to enrollment
- Compulsions need to involve movement of the hands and/or arms so that the sleeve is able to detect participant's actions (cannot be solely mental or verbal compulsions)
- Ability to understand procedure-related instructions and to complete study assessments in English, and ability to comply with protocol requirements (e.g., procedure visits, treatment schedule, follow-up visit schedule, evaluations, etc.), in the opinion of the Principal Investigator
- Willingness and ability to provide written agreement to allow any and all forms of communication between the research team and treating clinician(s) 8 Willingness and ability to provide informed consent, in the opinion of the Principal Investigator
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
Unable to undergo MRI scan
- Presence of metallic implants or devices or tattoos
- Claustrophobia or severe anxiety
- Inability to remain still for duration of scan
- Inability to fit and wear the ATTN201 device for the entire
Exclusion criteria for IRB study #853085 include:
- Hearing loss that, in the opinion of the Principal Investigator, an audiologist, or a treating physician, is likely to affect the subject's ability to comply with all of the requirements of the study, or may affect the integrity of the study data
- Pregnancy - this is an exclusion criterion because we will be intentionally increasing anxiety in participants to evaluate optimal strategies to provoke distress and then promote relaxation
- Any past or present medical condition, disease, disorder, or injury that, in the opinion of the Principal Investigator, may reduce or hinder the subject's ability to fully comply with all study requirements for the duration of the study or may impact, compromise, or affect the integrity of the data or results of the study.
- Have a previous injury or surgery which could affect the nerve distribution
- Have nerve damage (neuropathy)
- Have a diagnosed neuromuscular disorder
- Have a pacemaker
- Have a history of skin allergies, psoriasis eczema, dermatitis, or other skin inflammation conditions
- Compulsions cannot be completely mental or verbal actions, such as repeating words, counting objects, or performing mental rituals, and cannot involve only facial muscles/actions such as blinking or staring
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:LIFU Target Engagement Group
Participants in this single experimental group will undergo a series of low-intensity focused ultrasound (LIFU) sessions to evaluate safety and target engagement. Each participant will receive active LIFU stimulation at up to three personalized corticostriatal brain targets. The study utilizes a within-subject, sham-controlled design where participants receive both active LIFU and sham (placebo) stimulation across different sessions to compare physiological and clinical responses. |
Low-intensity focused ultrasound (LIFU) will be administered using the Attune ATTN201 device.
This intervention is characterized by a multifocal approach targeting three specific subcortical regions: the subthalamic nucleus (STN), the dorsal anterior cingulate cortex (dACC), and the ventral striatum (VS+).
Unlike clinical treatment trials, this is a target-engagement pilot study where each participant receives single sessions of sonication at these specific coordinates to evaluate acute physiological and symptomatic changes.
The intervention includes a within-subject sham-controlled component, where the device is positioned identically but no ultrasound energy is delivered.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Symptom Intensity through VAS score
大体时间:From the first visit (Visit 1) through the final visit (Visit 10), approximately 6 weeks.
|
This outcome evaluates the change in symptom intensity using Visual Analog Scales (VAS) scores.
VAS include questions regarding urges to compulse/resist compulsions and subjective units of distress (SUDs), measure the intensity of a patient's impulse to carry out or control and inhibit these compulsions, and the amount of distress they feel, and are on a scale between 0-100, where higher scores signify greater symptom severity.
|
From the first visit (Visit 1) through the final visit (Visit 10), approximately 6 weeks.
|
|
Changes in Imaging between Pre- and Post-Intervention
大体时间:Before the first visit (Visit 1) and after the final visit (Visit 10), approximately 6 weeks
|
This outcome measure evaluates safety and efficacy through neuroimaging conducted prior to and following the intervention.
These measures are intended to assess potential effects and target engagement associated with LIFU.
Efficacy measures will include changes in MRI-derived metrics (e.g., functional connectivity and/or regional activation in predefined regions of interest associated with the stimulation target).
Safety is assessed by the presence of new or worsening structural abnormalities, including edema, hemorrhage, or tissue injury.
|
Before the first visit (Visit 1) and after the final visit (Visit 10), approximately 6 weeks
|
|
Incidence of Adverse Events Assesed by Symptom Checklist
大体时间:Immediately after each intervention session and up to 24 hours post-intervention, assessed across the intervention period (Visits 6-9).
|
This outcome measure evaluates the incidence and severity of adverse events using a structured symptomatic checklist survey administered throughout the study period.
The checklist captures the presence, frequency, and severity of potential adverse symptoms.
Adverse events will be categorized by type, relatedness, and severity.
|
Immediately after each intervention session and up to 24 hours post-intervention, assessed across the intervention period (Visits 6-9).
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Physiological Changes Measured by EMG
大体时间:Baseline through end of intervention period (Visits 2-9), with EMG data collected at every in-person visit, approximately 4 weeks.
|
This outcome measure evaluates changes in muscle activity using surface electromyography (EMG) recorded from the forearm during sessions.
EMG signals will be collected continuously and processed using standardized pipelines.
Metrics will include various features (e.g., SNR (dB)) over defined time windows.
Change in muscle activity will be assessed by comparing pre-sonication values to post-sonication values.
|
Baseline through end of intervention period (Visits 2-9), with EMG data collected at every in-person visit, approximately 4 weeks.
|
|
Change in Y-BOCS score after sonication
大体时间:From the first baseline visit (Visit 1) through the final visit (Visit 10).
|
This outcome measures changes in Obsessive-Compulsive symptom severity using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), administered by a trained clinician.
Scores range from 0-40, with higher scores representing greater symptom severity.
|
From the first baseline visit (Visit 1) through the final visit (Visit 10).
|
|
Change in Acceleration Measured by IMU
大体时间:Baseline through end of intervention period (Visits 2-9), with IMU data collected at every in-person visit, approximately 4 weeks.
|
This outcome measure evaluates changes in forearm movement amplitude using inertial measurement unit (IMU)-derived acceleration data.
Acceleration (m/s²) will be recorded continuously from a microcontroller-based IMU placed on the participant's forearm during in-person sessions and processed using standardized signal processing pipelines.
Change in movement amplitude will be assessed by comparing pre-sonication and post-sonication values.
|
Baseline through end of intervention period (Visits 2-9), with IMU data collected at every in-person visit, approximately 4 weeks.
|
|
Change in Angular Velocity Measured by IMU
大体时间:Baseline through end of intervention period (Visits 2-9), with IMU data collected at every in-person visit, approximately 4 weeks.
|
This outcome measure evaluates changes in forearm rotational movement using inertial measurement unit (IMU)-derived angular velocity data.
Angular velocity (°/s) will be recorded continuously from a microcontroller-based IMU placed on the participant's forearm during in-person sessions and processed using standardized signal processing pipelines.
Change in rotational movement will be assessed by comparing pre-sonication and post-sonication values.
|
Baseline through end of intervention period (Visits 2-9), with IMU data collected at every in-person visit, approximately 4 weeks.
|
|
Change in Heart Rate Assessed by Photoplethysmography (PPG)
大体时间:Baseline through end of intervention period (Visits 2-9), with PPG data collected at every in-person visit, approximately 6 weeks.
|
This outcome evaluates changes in heart rate activity using photoplethysmography (PPG) recorded during sessions.
PPG signals will be collected from sensors placed on the participant and processed using standardized pipelines.
Changes in physiological response will be assessed by comparing pre to post-sonication values.
|
Baseline through end of intervention period (Visits 2-9), with PPG data collected at every in-person visit, approximately 6 weeks.
|
合作者和调查者
调查人员
- 首席研究员:Katherine Scangos, MD, PhD、University of Pennsylvania
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.